

Ti Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595980/publications.pdf>

Version: 2024-02-01

36
papers

1,569
citations

394421

19
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

2475
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2022, 162, 238-252.	1.3	25
2	The functions and prognostic value of KrÄ¼ppelâ€like factors in breast cancer. <i>Cancer Cell International</i> , 2022, 22, 23.	4.1	13
3	Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1001-1014.	4.2	29
4	Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16124-e16124.	1.6	5
5	Mild chronic hypoxia-induced HIF-2Î± interacts with c-MYC through competition with HIF-1Î± to induce hepatocellular carcinoma cell proliferation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1151-1166.	4.4	9
6	The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. <i>Cancer Management and Research</i> , 2021, Volume 13, 6989-6998.	1.9	5
7	High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma. <i>Oncology Letters</i> , 2021, 21, 69.	1.8	0
8	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 729764.	2.8	28
9	Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma. <i>BioScience Trends</i> , 2021, 15, 397-405.	3.4	9
10	Resection of â€œdown-stagedâ€ advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report. <i>Translational Cancer Research</i> , 2020, 9, 4999-5007.	1.0	0
11	Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1047-1047.	1.7	23
12	The novel miR-1269b-regulated protein SVEP1 induces hepatocellular carcinoma proliferation and metastasis likely through the PI3K/Akt pathway. <i>Cell Death and Disease</i> , 2020, 11, 320.	6.3	26
13	Cross talk between oxidative stress and hypoxia via thioredoxin and HIFâ€2Î± drives metastasis of hepatocellular carcinoma. <i>FASEB Journal</i> , 2020, 34, 5892-5905.	0.5	18
14	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <i>Liver Cancer</i> , 2020, 9, 682-720.	7.7	427
15	<p>Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3163-3173.	1.9	7
16	Systemic treatment of advanced or recurrent biliary tract cancer. <i>BioScience Trends</i> , 2020, 14, 328-341.	3.4	29
17	Apatinib as an alternative therapy for advanced hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 766-774.	2.0	10
18	High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma. <i>Oncology Letters</i> , 2020, 21, 69.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2019, 65, 905-915.	3.2	57
20	Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF- κ B signaling. <i>Experimental Cell Research</i> , 2018, 365, 12-23.	2.6	31
21	Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. <i>Pancreatology</i> , 2018, 18, 983-989.	1.1	6
22	miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. <i>Journal of Hematology and Oncology</i> , 2018, 11, 12.	17.0	156
23	Different but synergistic effects of bone marrow-derived VEGFR2 ⁺ and VEGFR2 ⁺ CD45 ⁺ cells during hepatocellular carcinoma progression. <i>Oncology Letters</i> , 2017, 13, 63-68.	1.8	3
24	Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. <i>Cancer Science</i> , 2017, 108, 1338-1346.	3.9	36
25	Surgery for Duodenal Gastrointestinal Stromal Tumors: A Single-Center Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3167-3176.	2.3	11
26	Apatinib is effective for treatment of advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 105596-105605.	1.8	45
27	Shanghai Score. <i>Chinese Medical Journal</i> , 2017, 130, 2650-2660.	2.3	18
28	MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways. <i>Oncotarget</i> , 2017, 8, 31745-31757.	1.8	41
29	Gastrin regulates ABCG2 to promote the migration, invasion and side populations in pancreatic cancer cells via activation of NF- κ B signaling. <i>Experimental Cell Research</i> , 2016, 346, 74-84.	2.6	16
30	Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 1005-1014.	1.1	33
31	Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. <i>Cancer Science</i> , 2016, 107, 507-513.	3.9	31
32	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. <i>Journal of Hematology and Oncology</i> , 2016, 9, 20.	17.0	52
33	Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1 α and contributes to chemoresistance in pancreatic cancer cells. <i>Cancer Biology and Therapy</i> , 2016, 17, 188-198.	3.4	79
34	Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 998-1008.	1.3	178
35	HIF-2 α regulates CDCP1 to promote PKC δ -mediated migration in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 1651-1662.	1.8	25
36	Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1125-1134.	1.0	33